NJ-FORK-&-GOOD
14.3.2023 13:01:48 CET | Business Wire | Press release
After four years of being in stealth, Fork and Good is emerging with the launch of its pilot facility in Jersey City, where it will initially focus on producing cultivated pork with the goal of expanding to other types of meat in the future. The company has raised $22 million to date from investors, led by True Ventures with participation from Leaps by Bayer, Collaborative Fund, Firstminute, Green Monday, Starlight, and others.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005208/en/
Steamed dumplings made with delicious Fork & Good cultivated pork (Photo: Business Wire)
Fork and Good is working to offset an existential crisis in conventional pork farming caused by a rise in viral diseases and antibiotic resistance, shrinking water and land resources, as well as concerns about its environmental impact. Combined, these factors have weakened the pork supply chain and contributed to price volatility that threatens to put meat out of reach for many consumers in the near future.
“To sustainably feed 10 billion people by 2050, we need to prioritize the development of alternative protein sources that are both nutritious and affordable at scale, using a fraction of the resources required today. We're excited to see Fork and Good making progress toward this vision,” said Juergen Eckhardt, Head of Leaps by Bayer.
Fork and Good’s initial focus on ground pork aims to help solve supply chain instability in the massive $820 billion global pork market. Its approach is differentiated at the start, as it cultivates muscle cells instead of stem cells, which allows for simpler, cheaper production. Simpler because they only grow meat cells. Cheaper because they don’t need to modify stem cells or other types of cells. Instead of growing cells using scaffolds, the company uses a patented bioprocess and unique bioreactors that increase yield and allow for higher density of production.
“Achieving high yields at an affordable price point is incredibly complex, and Fork and Good is uniquely equipped for the task,” said Adam D’Augelli, True Ventures. “Its Jersey City facility can produce six to ten times more pork per square foot than would be possible using traditional farming methods, with far less water and minimal impact on the surrounding ecosystem."
“Opening our pilot facility brings us one step closer to fulfilling our mission of producing cultivated pork that is both delicious and accessible,” added Niya Gupta, Fork and Good co-founder and CEO. “Given the hype in the space, we didn’t want to go public until we had something real.”
Niya is no stranger to the two-pronged challenge of yield and affordability; prior to Fork and Good, she co-founded ComCrop, an urban farming startup in Singapore that leverages hydroponics to grow large volumes of produce in a small space.
“From my experience in hydroponics, it became clear that low yield was the reason cultivated meat was so expensive,” said Niya. “We measure yield by feed conversion in livestock, and it was too low in cultivated meat. Our feed conversion is already close to that for pigs and we’re on track to be better.”
Niya’s agricultural knowledge is augmented by decades of scientific expertise from co-founder and Chief Scientific Officer Gabor Forgacs. A pioneering biophysicist with a 30+ year academic career, Gabor first introduced the world to cultivated meat on the TEDMED stage in 2011. He is the Scientific Founder of Organovo, a bioprinting company, and Modern Meadow, the first cultivated meat company that today engineers bio-fabricated materials that limit greenhouse gas emissions.
“Making cultivated meat does not require fundamentally new science,” explained Gabor. “Increasing yield at scale requires true innovation. That’s why we’ve focused so much on the process, patenting an approach that is both innovative and economically sound.”
Fork and Good began with a sense of urgency around bringing cultivated meat to market, and is now forging partnerships with food industry leaders to help ensure a future where everyone can access safe, humanely-produced meat that is good for people and the planet.
ABOUT FORK AND GOOD
From its facility in Jersey City, Fork & Good is on a mission to grow the best of meat for everyone, everywhere. The company takes a novel approach to cultivating meat by growing muscle cells directly in proprietary bioreactors for maximum flavor and nutritional value—while drastically reducing the amount of land and water used in conventional livestock production. The team has 150+ years of combined experience that spans food, agriculture, and science, and is committed to helping build the industry in a safe, transparent way. Learn more at: www.forkandgood.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005208/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
